Literature DB >> 11155579

Antimalarials.

M J Van Beek1, W W Piette.   

Abstract

Antimalarial medications have become the parenteral drugs of choice for treating the cutaneous manifestations of lupus erythematosus. The immune-modulating activity of these agents makes them useful in a variety of other dermatoses. With prudent dosage and monitoring, these agents can be used safely and effectively in the treatment and management of dermatologic disease.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11155579     DOI： 10.1016/s0733-8635(05)70236-9

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN： 0733-8635            Impact factor:   3.478


  10 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

Review 2.  Primary cicatricial alopecia: diagnosis and treatment.

Authors:  Rebecca Filbrandt; Nicholas Rufaut; Leslie Jones; Rodney Sinclair
Journal:  CMAJ       Date:  2013-05-21       Impact factor: 8.262

Review 3.  New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.

Authors:  Daniel J Wallace; Vineet S Gudsoorkar; Michael H Weisman; Swamy R Venuturupalli
Journal:  Nat Rev Rheumatol       Date:  2012-07-17       Impact factor: 20.543

4.  Antagonist-mediated down-regulation of Toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus.

Authors:  Shui-Lian Yu; Paul K S Chan; Chun-Kwok Wong; Cheuk-Chun Szeto; Suzanne C Ho; Karine So; May M Y Yu; So-Fan Yim; Tak-Hong Cheung; Martin C S Wong; Jo L K Cheung; Apple C M Yeung; Edmund K Li; Lai-Shan Tam
Journal:  Arthritis Res Ther       Date:  2012-04-18       Impact factor: 5.156

5.  Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease.

Authors:  Vicente Giner Galvañ; María Rosa Oltra; Diego Rueda; María José Esteban; Josep Redón
Journal:  Clin Rheumatol       Date:  2006-03-31       Impact factor: 3.650

6.  Down-regulated NOD2 by immunosuppressants in peripheral blood cells in patients with SLE reduces the muramyl dipeptide-induced IL-10 production.

Authors:  Shui-Lian Yu; Chun-Kwok Wong; Purple Tsz-Yan Wong; Da-Peng Chen; Cheuk-Chun Szeto; Edmund K Li; Lai-Shan Tam
Journal:  PLoS One       Date:  2011-08-19       Impact factor: 3.240

Review 7.  Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.

Authors:  Domenico Plantone; Tatiana Koudriavtseva
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 3.580

Review 8.  Antimalarials - are they effective and safe in rheumatic diseases?

Authors:  Ewa Haładyj; Mariusz Sikora; Anna Felis-Giemza; Marzena Olesińska
Journal:  Reumatologia       Date:  2018-06-30

Review 9.  New concepts in antimalarial use and mode of action in dermatology.

Authors:  Sunil Kalia; Jan P Dutz
Journal:  Dermatol Ther       Date:  2007 Jul-Aug       Impact factor: 2.851

10.  Chloroquine Treatment Suppresses Mucosal Inflammation in a Mouse Model of Eosinophilic Chronic Rhinosinusitis.

Authors:  Mi Ra Choi; Jun Xu; Seulgi Lee; Sun Hee Yeon; Soo Kyoung Park; Ki Sang Rha; Yong Min Kim
Journal:  Allergy Asthma Immunol Res       Date:  2020-11       Impact factor: 5.764
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.